To provide the information your oncologist is not telling you or doesn't have the time to!
Stay Informed About the Latest Oncology Breakthroughs
Explore the forefront of oncological research with our “Research Advances” category. Discover cutting-edge studies, innovative treatments, and scientific insights into cancer. Stay up-to-date with the latest breakthroughs and advancements in the field of oncology to make informed decisions about your health or that of your loved ones. Dive into the world of scientific progress and gain a deeper understanding of how research is shaping the future of cancer care.
The journey of understanding and treating metastatic bladder cancer has been marked by both challenges and triumphs. This cancer, which starts in the lining of the bladder and spreads beyond, represents a critical area in oncology due to its high incidence and aggressive nature. As per the latest statistics, metastatic bladder cancer accounts for about …
Turning the Tide Against Platinum-Resistant Ovarian Cancer In the ever-evolving landscape of cancer treatment, ovarian cancer remains one of the most challenging battles. Platinum-resistant ovarian cancer, in particular, presents a formidable foe, often leaving patients and healthcare providers grappling with limited treatment options. But amidst this struggle, a beacon of hope emerges with the advent …
Unveiling a New Era in Colorectal Cancer Treatment: The Promise of KRAS G12C Inhibition Colorectal cancer stands as one of the most common and deadly forms of cancer worldwide. Despite advances in treatment, the search for more effective and targeted therapies continues. A significant breakthrough in this quest is the understanding and targeting of specific …
In the ongoing battle against cervical cancer, a ray of hope emerges with the FDA’s recent approval of a groundbreaking treatment approach. For women grappling with advanced stages of this disease, this marks a significant advancement, offering new possibilities in their treatment journey. Understanding Cervical Cancer: Cervical cancer, a malignancy arising in the cervix, presents …
New data published in NEJM may new treatment options for patients dealing with metastatic small cell carcinoma! Small-cell lung cancer (SCLC) stands as one of the most aggressive forms of cancer, often leaving patients and their families grappling with limited treatment options and a prognosis that can seem disheartening. But amidst these challenges, there emerges …
If you or a loved one is battling locally advanced or metastatic urothelial cancer (la/mUC), there’s groundbreaking news to share. On December 15, 2023, the Food and Drug Administration (FDA) gave the green light to a dynamic combination of treatments: enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda). This approval is especially significant for patients ineligible for …
On December 14, 2023, the FDA gave the green light to belzutifan (Welireg, Merck & Co., Inc.), offering new hope for individuals battling advanced kidney cancer. It’s like unlocking a powerful tool after trying different strategies. Understanding Belzutifan’s Power Against Kidney Cancer Imagine your body as a bustling city with the kidneys playing the role …
Empowering Hope: A Breakthrough in CLL/SLL Treatment On December 1, 2023, the Food and Drug Administration (FDA) delivered a beacon of hope by granting accelerated approval to pirtobrutinib (Jaypirca, Eli Lilly and Company). This approval is a significant stride in the treatment landscape for adults facing chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) …
On December 13, 2023, the Food and Drug Administration (FDA) achieved a significant breakthrough by granting approval to eflornithine (IWILFIN, USWM, LLC) for use in both adult and pediatric patients facing the challenges of high-risk neuroblastoma (HRNB). This groundbreaking decision marks the first-ever FDA approval of a therapy designed to reduce the risk of relapse …
In a groundbreaking move, the Food and Drug Administration (FDA) has granted approval for enzalutamide (Xtandi, Astellas Pharma US, Inc.) to address non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence. This significant development brings renewed hope for patients at high risk for metastasis. The Road to Approval: EMBARK Trial Insights In the EMBARK clinical trial …